Pembrolizumab in Children, Adolescents, and Young Adults with High-Risk Classic Hodgkin Lymphoma (cHL) with Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study
Year: 2024
Type: conference-abstract
Source: Blood
Authors: Christine Mauz-Koerholz, Luciana Vinti, Stephen Daw, Antony Ceraulo, Gerard Michel, Michaela Cepelova, Lorena Valero-Arrese, Franca Fagioli, Stéphane Ducassou, Salvatore Buffardi, Thierry Leblanc, Bradford S Hoppe, Frank G. Keller, Kara M. Kelly, Lisa Giulino Roth, Judith Landman-Parker, Juan Shen, Pallavi Pillai, Rushdia Yusuf, Auke Beishuizen
Institutions: Justus-Liebig-Universität Gießen, Martin Luther University Halle-Wittenberg, Bambino Gesù Children's Hospital, Istituti di Ricovero e Cura a Carattere Scientifico, University College London Hospitals NHS Foundation Trust, Institut d’Hématologie et d’Oncologie Pédiatrique, Hôpital de la Timone, Charles University, University Hospital in Motol, Vall d'Hebron Hospital Universitari, Ospedale Regina Margherita, University of Turin, Centre Hospitalier Universitaire de Bordeaux, Hôpital Pellegrin, Hôpital Robert-Debré, Mayo Clinic in Florida, Henrietta Egleston Hospital for Children, Children's Healthcare of Atlanta, Roswell Park Comprehensive Cancer Center, University at Buffalo, State University of New York, Weill Cornell Medicine, Sorbonne Université, Hôpital Armand-Trousseau, Merck & Co., Inc., Rahway, NJ, USA (United States), Princess Máxima Center
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4405038853